# Talk:Heparin-induced thrombocytopenia

cross posted
Thrombocytopenia#Heparin-induced thrombocytopenia and thrombosis (HITT) should be synchronized with Heparin-induced thrombocytopenia#Treatment, and summarize it.  Could an expert do this please? --Hroðulf (or Hrothulf) (Talk) 09:12, 22 May 2008 (UTC)

Four patients with spontaneous HIT: doi:10.1016/j.amjmed.2008.03.012. Primary research but possibly worth mentioning. JFW | T@lk 12:16, 26 June 2008 (UTC)

ACCP guideline doi:10.1378/chest.08-0677 JFW | T@lk 01:14, 3 October 2008 (UTC)

Once I get around to improving this article, I intend to use the following sources:

Ahmed I, Majeed A, Powell R. Heparin induced thrombocytopenia: diagnosis and management update. Postgrad Med J 2007;83(983):575‐82. PMID 17823223. doi:10.1136/pgmj.2007.059188
Keeling D, Davidson S, Watson H. The management of heparin-induced thrombocytopenia. Br J Haematol 2006;133(3):259‐69. PMID 16643427. doi:10.1111/j.1365-2141.2006.06018.x
Selleng K, Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia in intensive care patients. Crit Care Med 2007;35(4):1165‐76. PMID 17334253. doi:10.1097/01.CCM.0000259538.02375.A5
Warkentin TE. Think of HIT. Hematology Am Soc Hematol Educ Program 2006:408‐14. PMID 17124091. doi:10.1182/asheducation-2006.1.408
Warkentin TE, Greinacher A, Koster A, Lincoff AM (2008). "Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)". Chest. 133 (6 Suppl): 340S – 380S. doi:10.1378/chest.08-0677. PMID 18574270. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
Let's see what happens. JFW | T@lk 22:30, 23 November 2008 (UTC)

I don't usually do this, but today I had to refactor some content that was standing in the way: here. Much of the content was unsourced despite making numerical claims, and most of the sources were primary sources. Finally, much of the content was highly technical. I will be populating sections per WP:MEDMOS in due course. Please bear with me. JFW | T@lk 22:16, 25 November 2008 (UTC)

doi:10.1111/j.1538-7836.2009.03335.x JFW | T@lk 23:24, 23 July 2009 (UTC)

I had completely overlooked:

Arepally GM, Ortel TL (2006). "Clinical practice. Heparin-induced thrombocytopenia". N. Engl. J. Med. 355 (8): 809–17. doi:10.1056/NEJMcp052967. PMID 16928996. {{cite journal}}: Unknown parameter |month= ignored (help)
Let's see if I can get hold of it. JFW | T@lk 12:57, 9 August 2009 (UTC)

As usual this article has been lying fallow because I was too chicken to write a good "treatment" section. I think we need to cover all three licensed anticoagulants, their monitoring and drawbacks. Perhaps a bit about the troubles about setting the target for lepirudin. JFW | T@lk 23:18, 8 September 2009 (UTC)

Similar to [1] or [2] Doc James (talk · contribs · email) 08:47, 15 December 2009 (UTC)

Haven't seen any. Have you got a few? JFW | T@lk 20:09, 15 December 2009 (UTC)
No it is no very common.  Will keep my eyes open a get a picture when possible.  That uptodate article I sent you expands a bit of epidemiology.  As we switch over to LMWH HIT will be less common.Doc James (talk · contribs · email) 20:14, 15 December 2009 (UTC)
Warkentin is a bit more cautious about LMWH being less HIT-ogenic. The last case I treated was due to dalteparin. JFW | T@lk 23:38, 22 December 2009 (UTC)

I saw that the article mentioned that heparin is not naturally occurring, but that is obviously false. I cited my edit. I'm not a Wikipedia person, hope I did it right. 68.46.171.223 (talk)  —Preceding undated comment added 00:11, 22 February 2010 (UTC). 

The problem is that your edit introduced a non-sequitur. Pharmacological heparin is clearly immunogenic and your edit doesn't explain that. Please revise your contribution. JFW | T@lk 19:58, 22 February 2010 (UTC)

A very large data set (RIETE) shows UFH indeed carries a higher risk than LMWH. doi:10.1111/j.1538-7836.2011.04402.x JFW | T@lk 07:49, 21 September 2011 (UTC)

The report does not seem to discuss confirmation of the diagnosis with anti-PF4 or serotonin release assays. JFW | T@lk 07:52, 21 September 2011 (UTC)

doi:10.1111/j.1538-7836.2011.04536.x is an ISTH working group report on standards in HITT diagnosis. Accepted for publication, but still a bit raw to be cited. JFW | T@lk 22:37, 18 October 2011 (UTC)

doi:10.1111/bjh.12059 is the new version of the British guidelines. May need to review those and update the article. JFW | T@lk 21:42, 15 October 2012 (UTC)
doi:10.1111/jth.12153 is a systematic review on HIT in children. Again pre-publication, but seems MEDRS and needs following up/incorporation. JFW | T@lk 16:49, 30 January 2013 (UTC)
doi:10.1056/NEJMct1206642 NEJM review on treatment. JFW | T@lk 07:08, 21 February 2013 (UTC)

FYI, a new review in NEJM is out, with some good info such as the use of fondaparinux for treatment; probably a good time to update the treatment section anyways, now that Lepirudin is off the market. Yobol (talk) 01:26, 22 April 2013 (UTC)

I wish I had time for it. Perhaps in a little while I can update the article and get it to FA at the same time. JFW | T@lk 21:04, 29 April 2013 (UTC)

Recommendations for standardization of laboratory testing for drug-induced immune thrombocytopenia: communication from the SSC of the ISTH doi:10.1111/jth.12852 JFW | T@lk 21:27, 25 January 2015 (UTC)

Greinacher review: doi:10.1056/NEJMcp1411910 JFW | T@lk 08:05, 16 July 2015 (UTC)

Heparin-protamine antibodies doi:10.1111/jth.13405 JFW | T@lk 07:03, 7 July 2016 (UTC)

doi:10.1111/jth.13813 JFW | T@lk 11:59, 7 November 2017 (UTC)

Systematic review doi:10.1182/bloodadvances.2020002963 JFW | T@lk 11:28, 15 April 2021 (UTC)